Ganguly Sandip, Gargy Sumedha, Basu Archisman, Chatterjee Meheli, Ghosh Anik, Chakraborti Basumita, Biswas Bivas, Dabkara Deepak, Rai Shweta, Roy Arunava, Mathai Sonia, Bhaumik Jaydip, Ghosh Joydeep
Department of Medical Oncology, Tata Medical Center, 14 MAR (E-W), New Town, Rajarhat, Kolkata, West Bengal 700156, India.
Department of Gynaecology, Rajendra Institute of Medical Sciences, Ranchi 834009, India.
Ecancermedicalscience. 2021 Sep 14;15:1290. doi: 10.3332/ecancer.2021.1290. eCollection 2021.
Ovarian germ cell tumours constitute a heterogeneous group of neoplasm with malignant potential being seen in 5% of cases. There is limited data on treatment outcomes of patients with malignant ovarian germ cell tumours (MOGCT). Here, we present our hospital audit of patients with MOGCT.
This is a retrospective data review of patients with MOGCT treated between May 2011 and December 2019. Patients were treated with staging laparotomy and adjuvant chemotherapy, wherever applicable. Surveillance was allowed for those at low risk for recurrence. Clinicopathologic features and treatment details were recorded, and survival analysis was performed.
Sixty-five patients with a median age of 25 years (range: 11-52 years) were treated during the study period. The most common histology was immature teratoma in 35.3% of cases. International Federation of Gynecology and Obstetrics stage IC was the most common stage of presentation (47%). Surveillance was advised for 12.3% of cases. Systemic therapy was given in 51 (78%) patients. At a median follow-up of 46 months (range: 1-109 months), the median progression-free survival (PFS) was not reached. Five-year PFS was 79.3% (95% CI: 65.8-88). The most common toxicity was febrile neutropenia (22%) among those who received systemic therapy.
Immature teratoma was the most common histology in our series. The majority presented in the early stage. MOGCT is a highly curable disease with surgery and systemic therapy.
卵巢生殖细胞肿瘤是一组异质性肿瘤，5%的病例具有恶性潜能。关于恶性卵巢生殖细胞肿瘤（MOGCT）患者的治疗结果的数据有限。在此，我们展示我们医院对MOGCT患者的审核情况。
这是一项对2011年5月至2019年12月期间接受治疗的MOGCT患者的回顾性数据审查。患者在适用时接受分期剖腹手术和辅助化疗。对于复发风险低的患者允许进行监测。记录临床病理特征和治疗细节，并进行生存分析。
在研究期间治疗了65例患者，中位年龄为25岁（范围：11 - 52岁）。最常见的组织学类型是未成熟畸胎瘤，占病例的35.3%。国际妇产科联盟（FIGO）IC期是最常见的表现阶段（47%）。12.3%的病例建议进行监测。51例（78%）患者接受了全身治疗。中位随访46个月（范围：1 - 109个月），中位无进展生存期（PFS）未达到。5年PFS为79.3%（95%CI：65.8 - 88）。在接受全身治疗的患者中，最常见的毒性是发热性中性粒细胞减少（22%）。
在我们的系列中，未成熟畸胎瘤是最常见的组织学类型。大多数患者处于早期阶段。MOGCT通过手术和全身治疗是一种高度可治愈的疾病。
